What is the definition of Intensive Care Unit (ICU) acquired weakness, specifically neuromuscular weakness?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

ICU-acquired weakness (ICUAW) is a neuromuscular disorder characterized by symmetrical limb weakness that develops during an intensive care unit stay with no other identifiable cause, typically affecting both the peripheral nerves and muscles, resulting in a combination of critical illness polyneuropathy (CIP) and critical illness myopathy (CIM) 1.

Definition and Characteristics

ICUAW occurs in approximately 25-50% of patients who are critically ill for more than 7 days, particularly those with sepsis, multi-organ failure, or prolonged mechanical ventilation. The condition manifests as diffuse muscle weakness, reduced or absent deep tendon reflexes, and difficulty weaning from mechanical ventilation due to respiratory muscle involvement.

Diagnosis and Risk Factors

Diagnosis involves clinical examination using the Medical Research Council (MRC) sum score to assess muscle strength, electrophysiological studies, and sometimes muscle biopsy. Risk factors include sepsis, systemic inflammatory response syndrome, multiple organ failure, hyperglycemia, immobility, and certain medications like corticosteroids and neuromuscular blocking agents 1.

Prevention and Treatment

Prevention strategies focus on minimizing sedation, early mobilization, glycemic control, and avoiding unnecessary corticosteroids or neuromuscular blockers. Treatment primarily involves supportive care, physical therapy, and treating the underlying critical illness, with recovery potentially taking weeks to months and some patients experiencing long-term disability. According to the most recent guideline on positioning and early mobilisation in the critically ill by an expert panel, early mobilisation can minimize the development of ICUAW 1.

From the Research

Definition of ICU Acquired Weakness Neuromuscular

ICU acquired weakness (ICU-AW) is defined as clinically detected weakness in critically ill patients in whom there is no plausible etiology other than critical illness 2. This condition can be classified into three subcategories using electrophysiological methods:

  • Critical illness polyneuropathy
  • Critical illness myopathy
  • Critical illness neuromyopathy

Causes and Risk Factors

The exact causes of ICU-AW are not fully understood, but several risk factors have been identified, including:

  • Illness severity and organ failure
  • Age
  • Hyperglycemia
  • Parenteral nutrition
  • Drugs
  • Immobility 2, 3

Diagnosis and Management

Diagnosis of ICU-AW is clinical, supported by electrophysiology and other diagnostic tests such as muscle ultrasound 4. Management is essentially preventive, focusing on avoiding modifiable risk factors, especially duration of sedation and immobilization 2. Pharmacological approaches have been studied, but none have proven efficacy 2.

Impact on Patients

ICU-AW can result in longer hospital stays and increased mortality 2. It is a substantial contributor to long-term disability in survivors of critical illness, with some patients experiencing slow and incomplete recovery 4. Early mobilization and aggressive treatment of sepsis may improve outcomes 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Intensive care unit-acquired weakness.

Handbook of clinical neurology, 2017

Research

Intensive Care Unit-Acquired Weakness.

Neurologic clinics, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.